Biogen finalizes $900M settlement in false claims whistleblower suit
By 
Adrianne Appel2022-09-27T19:04:00
Biogen finalized a $900 million settlement concerning alleged kickbacks it paid to doctors to induce them to prescribe the company’s drugs and not those of its competitors, the Department of Justice (DOJ) announced Monday.
Biogen made the alleged payments to try and dampen competition for its multiple sclerosis (MS) drugs, including Avonex, Tysabri, and Tecfidera, according to the settlement.
The agreement, first disclosed by Biogen in July, ends years of litigation dating back to 2012, when former employee Michael Bawduniak blew the whistle on the alleged kickbacks. He filed a lawsuit against the company in U.S. District Court for the District of Massachusetts, citing violations of the False Claims Act (FCA).
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticlePharma, whistleblower lessons learned from $900M Biogen settlement
Experts discuss the ramifications of Biogen’s $900 million settlement for False Claims Act violations, including the $266.4 million whistleblower bounty in the case believed to be the largest single award under any government program.
-
ArticlePhilips to pay $1.3M in second kickback settlement in month
Philips RS North America agreed to pay approximately $1.3 million to settle charges it unlawfully paid kickbacks as part of its second resolution addressing alleged False Claims Act violations this month.
-
ArticleEssilor agrees to $22M settlement over kickback charges
Essilor, a manufacturer and distributor of optical lenses and equipment, will pay $22 million to settle allegations it paid kickbacks to spur sales in violation of the False Claims Act.
More from Regulatory Enforcement
-
News BriefFTC sues Uber over deceptive subscriptions, a rare move for consumers by Trump officials
The Federal Trade Commission (FTC) filed a lawsuit against Uber, alleging the ride-hailing company signed customers up for its Uber One subscription without consent, then made it hard for them to cancel. The move marks the U.S. government’s latest broadside against big tech companies, and the first major action from ...
-
News BriefCFPB pullback signals further shift toward industry-friendly regulation
The U.S. Consumer Financial Protection Bureau continues to unravel amid pressure from Trump administration officials to shutter the agency. Not only has the agency informed its employees that it will no longer be a watchdog for the financial services industry, it has also laid off employees despite court orders blocking ...
-
News BriefTrump’s CFPB, dismissing Comerica case, continues to cut down Biden-era lawsuits
The Consumer Financial Protection Bureau dropped yet another consumer protection lawsuit against a bank or fintech provider since Donald Trump was sworn in as president in January. This time, it was with Comerica Bank.